ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,567.19
      1.06%
      US Tech 100
      19,828.00
      0.95%
      Dow Jones
      39,375.87
      0.17%
      Brent Oil
      86.775
      0.00%
      Bitcoin
      56,301.52
      -0.61%
      Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Incyte Corporation (INCY)

      7. Incyte Corporation (INCY) News

      INCY

      Incyte (INCY)

      Incyte Corporation
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:INCY
      DateTimeSourceHeadlineSymbolCompany
      10/03/20229:55AMTipRanksMizuho Securities Remains a Hold on Incyte (INCY)NASDAQ:INCYIncyte Corporation
      10/03/20226:00AMBusiness WireIncyte Announces Agreement to Acquire Medicxi-backed Villaris Therapeutics and Auremolimab (VM6), an Anti-IL-15Rβ Monoclonal AntibodyNASDAQ:INCYIncyte Corporation
      09/27/20224:15AMTipRanksMizuho Securities Reaffirms Their Hold Rating on Incyte (INCY)NASDAQ:INCYIncyte Corporation
      09/11/20229:20PMTipRanksAnalysts Offer Insights on Healthcare Companies: Incyte (INCY), Icon (ICLR) and Dr Reddy’s Laboratories (RDY)NASDAQ:INCYIncyte Corporation
      09/11/20221:55AMTipRanksJMP Securities Reaffirms Their Buy Rating on Incyte (INCY)NASDAQ:INCYIncyte Corporation
      09/05/20229:46PMTipRanksIncyte (INCY) Receives a Buy from RBC CapitalNASDAQ:INCYIncyte Corporation
      09/05/20226:45PMTipRanksMizuho Securities Keeps Their Hold Rating on Incyte (INCY)NASDAQ:INCYIncyte Corporation
      08/27/20229:22AMBusiness WireIncyte annonce que le Pemazyre ® (pemigatinib) a été approuvé par la FDA en tant que premier et unique traitement ciblé des néoplasmes myéloïdes/lymphoïdes (NML) avec réarrangement du FGFR1NASDAQ:INCYIncyte Corporation
      08/27/20229:22AMBusiness WireIncyte gibt FDA-Zulassung von Pemazyre® (Pemigatinib) als erste und einzige zielgerichtete Behandlung für myeloische/lymphoide Neoplasien (MLN) mit FGFR1-Rearrangement bekanntNASDAQ:INCYIncyte Corporation
      08/26/202210:56AMDow Jones NewsIncyte Gets FDA Approval for Rare-Blood-Cancer TreatmentNASDAQ:INCYIncyte Corporation
      08/26/202210:00AMBusiness WireIncyte Announces FDA Approval of Pemazyre® (pemigatinib) as the First and Only Targeted Treatment for Myeloid/Lymphoid Neoplasms (MLNs) with FGFR1 RearrangementNASDAQ:INCYIncyte Corporation
      08/25/20225:33AMBusiness WireDaten aus dem Dermatologie-Portfolio von Incyte zur Präsentation auf dem Kongress der European Academy of Dermatology and Venereology (EADV) 2022 angenommenNASDAQ:INCYIncyte Corporation
      08/25/202212:18AMBusiness WireLes données du portefeuille dermatologique d'Incyte ont été acceptées pour être présentées lors du Congrès 2022 de l'Académie européenne de dermatologie et de vénérologie (EADV)NASDAQ:INCYIncyte Corporation
      08/24/20228:00AMBusiness WireData from Incyte’s Dermatology Portfolio Accepted for Presentation at the 2022 European Academy of Dermatology and Venereology (EADV) CongressNASDAQ:INCYIncyte Corporation
      08/23/20228:00AMBusiness WireIncyte to Present at Upcoming Investor ConferenceNASDAQ:INCYIncyte Corporation
      08/04/202211:23PMTipRanksSVB Securities Remains a Sell on Incyte (INCY)NASDAQ:INCYIncyte Corporation
      08/03/20229:49PMTipRanksAnalysts Offer Insights on Healthcare Companies: Incyte (INCY), Zimmer Biomet Holdings (ZBH) and Aptose Biosciences (APTO)NASDAQ:INCYIncyte Corporation
      08/03/20224:05PMTipRanksIncyte (INCY) Gets a Buy Rating from JMP SecuritiesNASDAQ:INCYIncyte Corporation
      08/03/202212:38PMTipRanksIncyte (INCY) Gets a Hold Rating from Morgan StanleyNASDAQ:INCYIncyte Corporation
      08/02/20228:15AMTipRanksAnalysts Offer Insights on Healthcare Companies: Emergent Biosolutions (EBS), Incyte (INCY) and Harmony Biosciences Holdings (HRMY)NASDAQ:INCYIncyte Corporation
      08/02/20227:26AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:INCYIncyte Corporation
      08/02/20227:00AMBusiness WireIncyte Reports 2022 Second Quarter Financial Results and Provides Updates on Key Clinical ProgramsNASDAQ:INCYIncyte Corporation
      07/23/20229:15AMTipRanksIncyte (INCY) Gets a Buy Rating from William BlairNASDAQ:INCYIncyte Corporation
      07/20/20224:45PMTipRanksJMP Securities Reiterates a Buy Rating on Incyte (INCY)NASDAQ:INCYIncyte Corporation
      07/20/20227:29AMBusiness WireIncyte erhält Zulassung der US-amerikanischen FDA für Opzelura™ (Ruxolitinib-Creme) für die Behandlung von VitiligoNASDAQ:INCYIncyte Corporation
      07/20/20227:22AMBusiness WireIncyte annonce l'approbation par la FDA américaine de la crème Opzelura™ (ruxolitinib) pour le traitement du vitiligoNASDAQ:INCYIncyte Corporation
      07/19/202211:15AMTipRanksMizuho Securities Keeps a Hold Rating on Incyte (INCY)NASDAQ:INCYIncyte Corporation
      07/18/20229:08PMBusiness WireIncyte Announces U.S. FDA Approval of Opzelura™ (ruxolitinib) Cream for the Treatment of VitiligoNASDAQ:INCYIncyte Corporation
      07/12/202210:01PMTipRanksIncyte (INCY) Receives a Hold from Mizuho SecuritiesNASDAQ:INCYIncyte Corporation
      07/12/20228:00AMBusiness WireIncyte to Report Second Quarter Financial ResultsNASDAQ:INCYIncyte Corporation
       Showing the most relevant articles for your search:NASDAQ:INCY